One-year glargine treatment can improve the course of lung disease in children and adolescents with cystic fibrosis and early glucose derangements

Pediatric Diabetes

Volumn 10, Issue 3, 2009, Pages 162-167

  Mozzillo, Enza ^a   Franzese, Adriana ^a   Valerio, Giuliana ^b   Sepe, Angela ^a   De Simone, Ilaria ^a   Mazzarella, Gianfranco ^c   Ferri, Pasqualina ^a   Raia, Valeria ^a  

^a UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^b UNIVERSITY OF NAPLES PARTHENOPE   (Italy)

^c De Luca and Rossano Hospital   (Italy)

Author keywords

BMI; CFRD; CGMS; FEV1; OGTT

Indexed keywords

HEMOGLOBIN A1C; INSULIN GLARGINE;

ADOLESCENT; ARTICLE; BLOOD GLUCOSE MONITORING; BODY MASS; CHILD; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYSTIC FIBROSIS; DISEASE COURSE; DISEASE EXACERBATION; FORCED EXPIRATORY VOLUME; GLUCOSE TOLERANCE; HUMAN; HYPERGLYCEMIA; IMPAIRED GLUCOSE TOLERANCE; LUNG DISEASE; MAJOR CLINICAL STUDY; ORAL GLUCOSE TOLERANCE TEST; OUTCOME ASSESSMENT; PRIORITY JOURNAL; SCORING SYSTEM; SCREENING; TREATMENT DURATION;

ADOLESCENT; BODY MASS INDEX; CHILD; CYSTIC FIBROSIS; DIABETES MELLITUS; FORCED EXPIRATORY VOLUME; GLUCOSE INTOLERANCE; GLUCOSE TOLERANCE TEST; GROWTH; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPERGLYCEMIA; HYPOGLYCEMIC AGENTS; INSULIN; LUNG DISEASES; SPIROMETRY; TREATMENT OUTCOME;

EID: 65449133165     PISSN: 1399543X     EISSN: 13995448     Source Type: Journal    
DOI: 10.1111/j.1399-5448.2008.00451.x     Document Type: Article

References (30)

1. Dodge JA, Lewis PA, Stanton M, Wilsher J. Cystic Fibrosis mortality and survival in the UK: 1947-2003. Eur Resp J 2007: 522-526.
2. Costa M, Potvin S, Berthiaume Y et al. Diabetes: A major co-morbidity of cystic fibrosis. Diabetes Metab 2005: 31: 221-232.
3. Koch C, Rainisio M, Madessani U et al. Presence of cystic fibrosis-related diabetes mellitus is tightly linked to poor lung function in patients with cystic fibrosis: Data from European Epidemiologic Registry of Cystic Fibrosis. Pediatr Pulmonol 2001: 32: 343-350.
4. Finkelstein SM, Wielinski CL, Elliott GR et al. Diabetes mellitus associated with cystic fibrosis. J Pediatr 1988: 112: 373-377.
5. Lanng S, Thorsteinsson B, Nerup J, Koch C. Influence of the development of diabetes mellitus on clinical status in patients with cystic fibrosis. Eur J Pediatr 1992: 151: 684-687.
6. Moran A, Doherty L, Wang X, Thomas W. Abnormal glucose metabolism in cystic fibrosis. J Pediatr 1998: 133: 10-16.
7. Milla CE, Warwik WJ, Moran A. Trends in pulmonary function in patients with cystic fibrosis correlate with the degree of glucose intolerance at baseline. Am J Resp Care Med 2000: 162: 891-895.
8. Schaedel C, de Monestrol I, Hjelte L et al. Predictors of deterioration of lung function in cystic fibrosis. Pediatr Pulmonol 2002: 33: 483-491.
9. Rolon MA, Benali K, Munck A et al. Cystic fibrosis-related diabetes mellitus: Clinical impact of prediabetes and effects of insulin therapy. Acta Paediatr 2001: 90: 860-867.
10. Dobson L, Hattersley AT, Tiley S, Elworthy S, Oades PJ, Sheldon CD. Clinical improvement in cystic fibrosis with early insulin treatment. Arch Dis Child 2002: 87: 430-431.
11. Nousia-Arvanitakis S, Galli-Tsinopoulou A, Karamouzis M. Insulin improves clinical status of patients with cystic fibrosis related diabetes mellitus. Acta Pediatr 2001: 90: 515-519.
12. Franzese A, Spagnuolo MI, Sepe A, Valerio G, Mozzillo E, Raia V. Can Glargine reduce the number of lung infections in patients with cystic fibrosis-related diabetes [letter]? Diabetes Care 2005: 28: 2333.
13. Bizzarri C, Lucidi V, Ciampalini P, Bella S, Russo B, Cappa M. Clinical effects of early treatment with insulin glargine in patients with cystic fibrosis and impaired glucose tolerance. J Endocrinol Invest 2006: 29: RC1-RC4.
14. Moran A. Diagnosis screening, and management of cystic fibrosis-related diabetes. Curr Diab Rep 2002: 2: 111-115.
15. Costa M, Potvin S, Hammana I et al. Increased glucose excursion in cystic fibrosis and its association with a worse clinical status. J Cys Fibros 2007: 6: 376-383.
16. Dobson L, Sheldon CD, Hattersley AT. Conventional measures underestimate glycaemia in cystic fibrosis patients. Diabet Med 2000: 21: 691-696.
17. Jefferies C, Solomon M, Perlman K, Sweezy N, Daneman D. Continuous glucose monitoring in adolescents with cystic fibrosis. J Pediatr 2005: 147: 396-398.
18. Franzese A, Valerio G, Buono P et al. Continuous glucose monitoring system in the screening of early glucose derangements in children and adolescents with cystic fibrosis. J Pediatr Endocrinol Metab 2008: 21(Suppl. 2): 109-116.
19. Mastrototaro J. The Minimed Continuous Glucose Monitoring System (CGMS). J Pediatr Endocrinol Metab 1999: 12: 751-758.
20. Goss CH, Burns JL. Exacerbations in cystic fibrosis 1: Epidemiology and pathogenesis. Thorax 2007: 62: 360-367.
21. Kuczmarski RJ, Ogden CL, Guo SS et al. 2000 CDC Growth Charts for the United States: Methods and development. Vital Health Stat 11: 1-190.
22. Cotes JE, Chinn DJ, Quanjer PH, Roca J, Yernault JC. Standardized lung function testing. Report working party. Standardization of lung function test. European Community for Coal and Steel. Bull Eur Physiopathol Respir 1983: 19: 1-82.
23. Löser C, Möllgaard A, Fölsch UR. Faecal elastase 1: A novel, highly sensitive, and specific tubeless pancreatic function test. Gut 1996: 39: 580-586.
24. Wagner MH, Bowser EK, Sherman JM, Francisco MP, Theriaque D, Novak DA. Comparison of steatocrit and fat absorption in persons with cystic fibrosis. J Pediatr Gastroenterol Nutr 2002: 35: 202-205.
25. Onady GM, Stolfi A. Insulin and oral agents for managing cystic fibrosis-related diabetes. Cochrane Database Syst Rev 2005: 20: CD004730.
26. Moran A, Basu R, Milla C, Jensen MD. Insulin regulation of free fatty acid kinetics in adult cystic fibrosis patients with impaired glucose tolerance. Metabolism 2004: 53: 1467-1472.
27. Lanng S, Thorsteinsson B, Erichsen G, Nerup J, Koch C. Glucose tolerance in cystic fibrosis. Arch Dis Child 1991: 66: 612-616.
28. Arora NS, Rochester DF. Respiratory muscle strength and maximal voluntary ventilation in undernourished patients. Am Rev Respir Dis 1982: 126: 5-8.
29. Arora NS, Rochester DF. Effect of body weight and muscularity on human diaphragm muscle mass, thickness, and area. J Appl Physiol 1982: 52: 64-70.
30. Schneiderman-Walker J, Wilkes DL, Strug L et al. Sex differences in habitual physical activity and lung function decline in children with cystic fibrosis. J Pediatr 2005: 147: 321-326.